Open navigation
Search
Search

Select your region

Jörn Witt
Partner

Dr. Jörn Witt, LL.M. (University of London)

Rechtsanwalt

Languages
  • English
Social media

Jörn Witt focuses on the life sciences and agrosciences sector and advises pharmaceutical companies, medical device manufacturers, agroscience companies as well as companies in related regulated industries. He covers regulatory and reimbursement matters and also assists his clients with drafting and negotiating cooperation and development agreements for business development purposes. Jörn furthermore represents his clients in contentious cases and regularly advises on transactions in the life sciences sector.

Jörn’s practice covers licensing and pharmaceutical law as well as drugs and medical devices advertising law. He also advises his clients on statutory health insurance law issues, in particular in the context of new forms of care, and on crop protection law. Across all industries, Jörn furthermore advises on intellectual property matters with a focus on trade mark and competition law as well as anti-counterfeiting campaigns.

He joined CMS in 2006 and has been a partner since 2013.

Awards & Recognitions
01
  • Quote
    Listed for Pharmaceutical Law
    Deutschlands beste Anwälte 2025 – Handelsblatt in Kooperation mit Best Lawyers
  • Quote
    Listed for Intellectual Property
    Deutschlands beste Anwälte 2025 – Handelsblatt in Kooperation mit Best Lawyers
  • Quote
    Listed for Biotechnology Law
    Deutschlands beste Anwälte 2025 – Handelsblatt in Kooperation mit Best Lawyers
  • Quote
    „Jörn Witt und Roland Wiering sind sehr empfehlenswert.“, Mandant
    The Legal 500 Deutschland, 2025
  • Quote
    „Oft empfohlen“ für Gesundheitswesen
    JUVE Handbuch, 2024/2025
  • Quote
    Listed for Pharmaceutical Law
    Deutschlands beste Anwälte 2024 – Handelsblatt in Kooperation mit Best Lawyers
  • Quote
    Listed for Intellectual Property
    Deutschlands beste Anwälte 2024 – Handelsblatt in Kooperation mit Best Lawyers
  • Quote
    „Oft empfohlen“ für Gesundheitswesen
    JUVE Handbuch, 2023/2024
  • Quote
    Listed for Pharmaceutical Law
    Deutschlands beste Anwälte 2023 – Handelsblatt in Kooperation mit Best Lawyers
  • Quote
    Listed for Intellectual Property
    Deutschlands beste Anwälte 2023 – Handelsblatt in Kooperation mit Best Lawyers
  • Quote
    "Jörn Witt: High quality standards. High level of commitment and dedication. Always maintains an overview in order to set priorities correctly. Very experienced, professional and approachable.", client
    The Legal 500 EMEA, 2023
  • Quote
    "The team behind leadership duo Thomas Manderla in Düsseldorf and Jörn Witt in Hamburg […] impresses with broad sector expertise"
    The Legal 500 EMEA, 2021
  • Quote
    "Recommended" for Pharmaceuticals and Healthcare
    JUVE German Commercial Law Firms 2022 (GCLF)
  • Quote
    "reliable, competent", "very knowledgeable and experienced, makes a huge contribution to strategies in legal disputes, excellent wing man who protects his own advances", clients
    JUVE German Commercial Law Firms 2022 (GCLF)
  • Quote
    "Jörn Witt is committed, professional, experienced and reliable.", client
    The Legal 500 EMEA, 2022
  • Quote
    „Oft empfohlen“ für Regulierung
    JUVE Handbuch, 2022/2023

Publications

  • Unlautere Nachahmung eines Medizinproduktes – Femur-Teil, zugleich Anmerkung zum BGH-Urteil vom 15.4.2010 - I ZR 145/08; MPR 2011, 42
  • Internet-Aktivitäten öffentlich-rechtlicher Rundfunkanstalten, Duncker & Humblot 2007

Education

  • Completed his PhD as a German Academic Scholarship Foundation scholar; topic: broadcasting law
  • 2006: Second state examination in law
  • Trainee lawyer in Hamburg
  • 2001 - 2004: Research assistant for Prof. Dr. Hubertus Gersdorf, University of Rostock
  • LL.M. at Queen Mary University of London as a German Academic Exchange Service scholar
  • 2000: First state examination in law
  • Law studies in Hamburg

Insights by Jörn

CMS at INTA 2026

02 May 2026

CMS at INTA 2025

17 May 2025

CMS wins with GE Healthcare in Federal Social Court

28 Mar 2023 4 min read

Key points paper of the federal government on cannabis legalization

09 Nov 2022 5 min read
Back to top Back to top